ABCC5 and prostate carcinoma: Similarly, in TCGA-PRAD (p = 0.026) and MSKCC (p = 0.013), prostate cancer patients with high ABCC5 expression also had shorter overall survival times than those with low ABCC5 expression (Figure 2H-I).